Abstract
The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Anti-Cancer Agents in Medicinal Chemistry
Title: SHP-1 in Cell-Cycle Regulation
Volume: 11 Issue: 1
Author(s): Pilar Lopez-Ruiz, Javier Rodriguez-Ubreva, Ariel Ernesto Cariaga, Maria Alicia Cortes and Begona Colas
Affiliation:
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Abstract: The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Export Options
About this article
Cite this article as:
Lopez-Ruiz Pilar, Rodriguez-Ubreva Javier, Ernesto Cariaga Ariel, Alicia Cortes Maria and Colas Begona, SHP-1 in Cell-Cycle Regulation, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941154
DOI https://dx.doi.org/10.2174/187152011794941154 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Thiomers, Mucoadhesion and Oral Delivery of Biomacromolecules
Current Drug Therapy Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Intramolecular Immunological Signal Hypothesis Revived - Structural Background of Signalling Revealed by Using Congo Red as a Specific Tool
Mini-Reviews in Medicinal Chemistry Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry A Nanotechnology-based Strategy to Increase the Efficiency of Cancer Diagnosis and Therapy: Folate-conjugated Gold Nanoparticles
Current Medicinal Chemistry Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors
Current Pharmaceutical Design Adnexal Masses in Premenopausal Reproductive Age Women
Current Women`s Health Reviews Lung Cancer- Current Clinical Profile and Diagnostic Challenges
Current Respiratory Medicine Reviews Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?
Current Medicinal Chemistry The Extent of Hydroxymethylfurfural Formation in Honey by Heating Temperature and Duration
Letters in Organic Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy Strategies in Prostate Cancer
Current Gene Therapy Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities
Anti-Cancer Agents in Medicinal Chemistry The Use of Synthetic Oligonucleotides as Protein Inhibitors and Anticode Drugs in Cancer Therapy: Accomplishments and Limitations
Current Cancer Drug Targets Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued)